Home / Transcripts / Yatharth Hospital & Trauma Care Services Limited (YATHARTH) · February 6, 2026

Yatharth Hospital & Trauma Care Services Limited (YATHARTH) Earnings Call Transcript

February 6, 2026

National Stock Exchange of India IN Health Care Health Care Providers and Services earnings 63 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, everyone, and welcome to the Q3 FY26 earnings conference call for Yatharth Hospital, hosted by Nuvama Wealth Management Limited. Please be reminded that all participant lines are in listen-only mode, and following the presentation's conclusion, there will be an opportunity for you to ask questions. If you require assistance during this call, you can signal an operator by pressing star, then zero on your touch-tone phone. Kindly note that this conference is being recorded. I now hand the conference over to Mr. Shrikant Akolkar from Nuvama Wealth Management Limited. Thank you, and over to you, sir.

Shrikant Akolkar analyst
#2

Hello, everyone, and good day. Thank you, Bhumi. We at Nuvama Wealth Management are pleased to welcome all of you to this earnings conference call covering Q3 and the nine months of FY26 for Yatharth Hospital & Trauma Care Services Limited. Joining us from management today are Mr. Yatharth Tyagi, Full-time Director; Mr. Amit Kumar Singh, Group Chief Executive Officer; Mr. Nitin Gupta, President, Finance, and Group Chief Operating Officer; Mr. Pankaj Prabhakar, Group Chief Financial Officer; Mr. Ashutosh Kumar Jha, Group Chief Strategy, M&A, and Investor Relations; and Mr. Sonu Goyal, Group Financial Controller. I'll now turn the call over to Mr. Yatharth Tyagi for his opening remarks. Thank you, and over to Yatharth.

Yatharth Tyagi executive
#3

Good afternoon, everyone, and welcome to the earnings conference call for Yatharth Hospital & Trauma Care Services Limited, covering the quarter that closed on December 31, 2025. The presentation on our earnings can be found on the stock exchange as well as on our website, and we hope you've had a chance to go through it. Q3 FY26 was another period of industry-leading results for Yatharth Hospitals, with revenue rising 46% YOY — a strong trajectory — as we posted our highest quarterly revenue and profitability ever. One standout item this quarter was how quickly our recently opened New Delhi and Faridabad Sector 20 hospitals have scaled up. During their first full quarter of operations, revenue from these hospitals came to INR 279 million, which is 9% of group revenues. Within only three months of launch, Faridabad Sector 20 has already hit a monthly revenue run rate of INR 7 to 8 crores, while New Delhi is running at close to INR 5 crores of monthly revenue run rate. All of the revenue at both hospitals — 100% — came from cash and PPA (Private Insurances), which shows the payer mix focus we had from day one of operations. On operating metrics, they also put up strong initial ARPOB performance, with New Delhi at approx. INR 40,000 and Faridabad Sector 20 at INR 36,000.

Yatharth Tyagi executive
#4

Those levers sit above the group average, which highlights the quality of case mix and the clinical offerings from day 1 at our new hospitals. With Faridabad Sector 20 now added alongside our Greater Faridabad Hospital, which began operations last fiscal, Yatharth has emerged as the most preferred healthcare chain in the Faridabad region. We achieved this through strategic investments in star clinicians, high-end and complex super specialties, and state-of-the-art technology, including robotics-enabled care from the inception. Our Greater Faridabad facility, which reached break-even in Quarter 1 FY26, continues to contribute meaningfully not only to revenue but also to profitability, with its EBITDA margin now approaching the group average. These outcomes reinforce the strong target identification, integration, and scale-up of capabilities, as well as our focus on achieving profitability in new facilities within short time frames. Turning to a recent expansion, the Agra Hospital is now fully integrated into the Yatharth network, effective February 1, 2026. The hospital is already a fully operational facility with strong visibility in its micro-market, and we are confident that it will contribute meaningfully to revenue and EBITDA from this quarter. Moving on, clinical excellence remains at the core of our value proposition.

Yatharth Tyagi executive
#5

This quarter, our teams carried out a number of advanced and complex interventions. These included a successful pan-plexus injury management that used a high-precision transfer of intercostal to musculocutaneous nerve to restore key motor functions. In a separate case involving a rare congenital urological condition, we performed advanced minimally invasive endourological surgery for a left ureteral with duplex collection system complicated by ureteric stones and severe hydronephrosis. We also completed a 13-peroral endoscopic myotomy (POEM) procedure within two months, which shows our leadership in scar-free endoscopic therapies across the region. These outcomes demonstrate the depth of clinical expertise throughout our network and reinforce our standing as a leading quaternary care provider. This quarter, some of our key clinicians were also recognized with NARCHI National Awards, which further strengthens our clinical reputation. With the Jewar Airport expected to start operations soon, we have sped up our medical value travel initiatives and they continue to gain traction. During the quarter, we broadened international outreach by running OPD operations in Mauritius, Nigeria, and Turkmenistan. We also hosted delegation visits and hospital tours from Afghanistan, Uzbekistan, and Tajikistan, strengthening our diplomatic and healthcare partnerships in this way. In addition, we held partner engagement events with stakeholders across Africa and Iraq. Going forward, we will stay focused on accelerating the ramp-up of new facilities such as New Delhi, Faridabad Sector 20, and Agra Hospitals, while continuing to drive operational efficiencies throughout the network.

Yatharth Tyagi executive
#6

We're already seeing encouraging signs from the recent CGHS price revision, which is benefiting both our top line and our bottom line. We also remain confident and committed to clinical excellence, disciplined execution, and strong governance, and we're confident in our ability to deliver sustained value to all our stakeholders. Quarter 3 has been an exceptional performance by the company, and we further expect that, due to the integration of the new hospitals in our network, Quarter 4 would even be better than the Quarter 3 numbers. With that, I would now like to hand over the call to Mr. Pankaj Prabhakar for a detailed financial update.

Pankaj Prabhakar executive
#7

Good afternoon, everyone. I'm happy to report that Yatharth Hospital turned in an outstanding performance this quarter. In Quarter 3 FY26, revenue came in at INR 3,205 million, which represents robust growth of 46% year-over-year and 15% quarter-over-quarter. That strong growth came from our existing hospitals, which maintained a solid 33% year-over-year growth trajectory, along with our newly operational hospital, which contributed INR 279 million in revenue, 9% of group revenue, in its first full quarter of operations. Occupancy across our hospital network was healthy at 67% during Quarter 3, with our key hospitals: Noida operating at 91%, Greater Noida at 74%, Noida Extension at 61%, and Jhansi Orchha at 72% during the quarter. Our newer facilities saw promising adoption, with healthy volume at our Greater Faridabad, New Delhi, and Faridabad Sector 20 hospitals, demonstrating Yatharth's position as a preferred healthcare provider in the region. Our ARPOB rose 10% year-over-year to INR 33,744 in Quarter 3, driven by our continued emphasis on improving our mix of high-value super specialties and investment in state-of-the-art medical infrastructure. Our Noida Extension Hospital achieved its highest-ever ARPOB of approx. INR 44,000, up 16% year-over-year, supported by approx.

Pankaj Prabhakar executive
#8

Super specialty services made up 70% of the contribution, and within that, oncology treatment accounted for 18%. Our New Delhi hospital, even in the early days of operation, reached an ARPOB of roughly INR 40,000, while Faridabad Sector 20 hit an ARPOB of INR 36,000 — both above the group average. At our other hospitals, Greater Noida and Jhansi Orchha, ARPOB came in at approximately INR 39,000, plus 14% year-over-year: INR 31,000, which is 8% year-over-year, and INR 14,000, respectively. Turning to profitability, we posted our highest-ever EBITDA of INR 742 million, a rise of 35% year-over-year. If we adjust for the initial ramp-up losses at our newly operationalized New Delhi and Faridabad Sector 20 hospitals, our adjusted EBITDA margin remained strong at 29.2%, driven by operating leverage, improved mix, and the positive effect of price revision in government business. Net profit after tax was INR 431 million, up 41% year-over-year, while adjusted tax rose 80% year-over-year. With a strong execution engine in place, we remain confident about sustaining the accelerated growth momentum while improving operational efficiencies and exploring new avenues for growth. Our robust balance sheet, with a strong net cash position, gives us ample financial headroom to capitalize on sustained growth opportunities as they arise.

Pankaj Prabhakar executive
#9

Appreciate everyone's time. At this point, I'd like to pass the call over to the moderator so we can move into the question-and-answer session. Thanks.

Operator operator
#10

Thanks a lot. We're moving into the question-and-answer portion now. If you'd like to pose a question, just hit star and one on your touch-tone phone. Should you want to drop out of the queue, press star and two. We ask that participants use their handsets when asking. Ladies and gentlemen, we'll pause briefly while the queue fills up. Our first question is from Priyanshu Jain at Infinity. Please go ahead.

Priyanshu Jain analyst
#11

Hi there. Can you hear me okay?

Operator operator
#12

Yes. Yes. Go right ahead.

Priyanshu Jain analyst
#13

Appreciate the chance to ask. Sir, my first question relates to the revenue mix. So as things stand now, at the close of Q3, how does revenue break down between cash and PPA on one side and the government side on the other?

Yatharth Tyagi executive
#14

Right now, government accounts for nearly 35% of revenue, and the rest splits evenly between cash and private insurance. This past quarter, given what the new hospitals have demonstrated on the cash and private insurance side, we feel quite confident that over the next several quarters we should be moving gradually toward lowering the government share, in line with our original target. My sense is that in two and a half years, the government portion ought to come down to somewhere around 25%-28%. Two years from now, we're targeting 25%-30%, roughly. Two years from now, government business should be under 30%.

Priyanshu Jain analyst
#15

Alright, so my next question concerns the brownfield expansion, since we're moving ahead with 3,000 beds. So, when do you expect that could be operational?

Yatharth Tyagi executive
#16

Right. So we're referring to adding close to 3,000 beds, which would bring the cumulative total up to 5,000 within the next three years — and as we've said, those deals will be announced over that same three-year window, while the hospitals themselves will become operational across 4 to 5 years, phased in over time.

Priyanshu Jain analyst
#17

All right. So as of right now, what does net cash on the balance sheet stand at, if we're looking at any acquisition down the road? And are we?

Pankaj Prabhakar executive
#18

As of 31st December, on a consolidated basis, our cash and bank position currently stands at nearly INR 200 crore.

Priyanshu Jain analyst
#19

All right. As of today, we're still aiming for any acquisition, since we've bought a lot of hospitals over the past few years. Are we still pursuing that?

Yatharth Tyagi executive
#20

Look, acquisitions are certainly going to take place in the years ahead. So we do sit in a solid, strong cash position, and beyond that we can always take on certain debt. That said, internal accruals are also quite strong. So I think by drawing on all three of those mixes, we're well positioned to fund our CapEx for the next good 3 years.

Priyanshu Jain analyst
#21

Alright, sir, just two more questions from me. What's the CapEx per bed right now, as of today, if we go ahead with it?

Pankaj Prabhakar executive
#22

Right now, we're looking at roughly INR 60 lakhs per bed for CapEx, since many of the hospitals we launched 10 years ago had fairly low construction and land costs at that point. Over time, we've moved up to upgraded medical equipment. If you take our newer hospitals — New Delhi and both of the Faridabad hospitals — CapEx per bed there runs considerably higher. My sense is that in those locations, CapEx per bed would be upwards of INR 80 to 90 lakhs per bed. That reflects the CapEx per bed plan as it stands today.

Priyanshu Jain analyst
#23

Alright. Sir, the final question concerns this. Sir, I simply wanted to ask, since there was a recent case in which a relative underwent knee replacement surgery — and just to give an example, it costs roughly INR 2 lakh in cash — is it possible that insurance, while hospitals do carry out this kind of practice in the cash segment, where if they go for INR 2 lakh, but if the patient holds an insurance policy, they raise it to INR 2.5 lakhs or INR 3 lakhs?

Amit Kumar Singh executive
#24

No, that is definitely not the case. What I mean is that the pricing has already been set. So, if the cash amount is, say, INR 2 lakh in fact, for the insurance it will be lower, effectively for us. I mean, what is the landing price for us? Because that agreement has been signed, and the rates are already frozen. So you cannot make a change. And this is not something where, if I wish, I can change it. So that is not how it is done. The cash will always be the higher figure, then there will be some insurance, and after that the government business. That is the practice.

Priyanshu Jain analyst
#25

Alright. Thanks, sir. That’s everything from me. Best of luck.

Operator operator
#26

Thanks. We'll take our next question from Surya Narayan Nayak, who is on the line from Sunidhi Securities. Go right ahead.

Surya Narayan Nayak analyst
#27

Good afternoon, sir. I hope you can hear me clearly. I have a couple of questions. First, could you shed some light on the newer hospitals and share the numbers — I mean the census beds and how the ramp-up strategy looks going forward for FY27? And on the Agra unit as well, same thing: if you could tell us the ARPOB we're currently enjoying, what the status of census beds is there, and what the plan is in FY27.

Amit Kumar Singh executive
#28

So right now our capacity stands at roughly 2,550 beds, and that figure takes in the 250 beds at Agra. All told, our plan is to reach somewhere between 5,000 and 6,000 beds, which is what we said in response to the earlier question too. So during the ramp-up phase, we'll be adding approximately 3,000 more beds over the next three to four years. As for occupancy, on a blended basis we're sitting at 67%. And ARPOB is at 33%.

Surya Narayan Nayak analyst
#29

No, sir. What I asked about was specifically the newer hospitals and the newer facilities — the more recent facilities in the NCR region and Agra. Yes.

Amit Kumar Singh executive
#30

Regarding Model Town in New Delhi, we’re running at about 38% occupancy across the 100 census beds. Our capacity there in New Delhi is roughly 300 beds, and we’ll bring that on as demand arrives over the coming quarters. Then we have another new hospital in Sector 20, Faridabad, where occupancy for this quarter is 43%, again with 125 beds at the operational level, and that facility has capacity for around 400 beds. In Agra, we only launched in February. We’ve just gotten it going, with roughly 150 beds currently operational, and we plan to grow that to around 250 beds over the coming quarters.

Surya Narayan Nayak analyst
#31

When it comes to the newer hospitals, should we be expecting 50% occupancy next year?

Amit Kumar Singh executive
#32

Sure, absolutely. So look at Faridabad—it launched only 3 months ago, about two and a half to 3 months back, and right now we have 125 beds up and running, with 43% occupancy. And that's without any panel—in fact, not even full-fledged insurance and PPA, correct? So those current numbers are certainly very encouraging. The same holds true for Delhi as well. We still have 100% of insurances to come—meaning all government channels, plus corporate and PSUs, which depend on the various states—negotiations are still underway. So I think by the end of quarter four, or perhaps the start of quarter four—sorry, over the next 2 months—we should be fully equipped with all the empowerments. After that, we expect occupancy above 50% in the quarters ahead. Turning to Agra, which we opened on 1st of February—current ARPOB, since it's an operating hospital, is presently, I think, around INR 26,000 in terms of ARPOB. With us there, starting with super specialties and the rest, we believe we can easily raise it by next quarter to somewhere between INR 30,000 and INR 32,000 in RPOF terms.

Surya Narayan Nayak analyst
#33

Alright. And as for the Agra unit next to the other facilities, from what we understand, the acquisition cost is somewhat on the higher side. So how do you intend to bring it in line with the other MCR region facilities? What about the case mix and all of that?

Amit Kumar Singh executive
#34

Okay, so look — Agra Hospital is, I'd call it, the finest facility of its kind not only in Agra but across a 100-kilometer radius throughout that entire region. It's a full super-specialty hospital, you know. Every piece of equipment is there, MRI and Cath Lab included. On top of that, there's room for expanding further. It holds full NABH accreditation. So there were several reasons we concluded the valuation was fair. The hospital is already operating. And over the last 12 months, if I look at it, revenue came in at roughly INR 45 crore to INR 50 crore, and it's now essentially EBITDA positive and P&L positive as well. So starting February, once it sits on our books, no additional losses are needed to get it to profitability. We factor that in as well to support the valuation, because normally, launching a brand-new hospital means 15 months and further cash losses before you reach profitability. But come February, it's already on our books. Not only does it add meaningfully on the revenue side, it also contributes to EBITDA and to profitability too. So we feel quite confident.

Amit Kumar Singh executive
#35

We've got big plans for Agra. We're already in the middle of bringing on top star doctors. In fact, this very week, Agra Hospital has received the da Vinci Surgical System — which will be one of the first robotic surgeries not only in Agra but across that region. So we believe Agra will make a meaningful contribution to our upcoming quarters.

Surya Narayan Nayak analyst
#36

On payer mix, I just want to get a sense — even with PPA, how much of a split could you provide between group policy and retail policy? The reason is that retail policy tends to be a bit more profitable than group policy. So could you give that breakdown?

Amit Kumar Singh executive
#37

I think by and large, yes — that's a group. What you're referring to, I believe, is mostly the corporate insurance side of things. On the retail side, yes, the count is always larger. Still, I'd say it likely lands around a 60%-40% split, since it also hinges on the area where you operate. Take Delhi NCR, for instance, where more corporates are located, right? There the percentage will look different. Whereas if you're operating in Agra, or perhaps Meerut, or another region where corporate spaces aren't as plentiful, that figure will come in lower. So there isn't going to be a standard answer here. It varies from unit to unit and depends on the area in which you operate.

Surya Narayan Nayak analyst
#38

No — because structurally, thanks to those GST advantages, the retail policy ought to go up. What I mean is, the quantum should increase. That's how I understand it. And structurally speaking, it's a positive. Also, thirdly, oncologists — I noticed that the percentage quantum of ours has stayed the same. So is there some facility-related limitation in what we offer, or is there room to raise it going forward?

Amit Kumar Singh executive
#39

Well, first off, the two aren't the same. Our pie has grown, correct? The percentage may appear comparable, but there's an absolute rise in volume and in the revenue that oncology brought in both this quarter and year-on-year. In fact, that rise is significant. It also should be noted that at the upcoming Faridabad and New Delhi hospitals, we'll be offering a full-scale oncology service as well, and those services haven't yet begun in this quarter. So going forward, at these two new hospitals of ours — because oncology requires five, six months to get going, to install the machines, and to complete bone marrow transplants and other high-end cancer surgeries — in the quarters ahead, oncology will also start at our new hospitals. And that is where you'll see the percentage go up as well, but also the absolute number. If I speak about oncology, it has gone up significantly. In fact, comparing year-over-year, oncology has risen from INR 63 crores to nearly INR 85 crores, which is a significant jump.

Surya Narayan Nayak analyst
#40

So do you have any guidance for oncology by itself going forward? I mean, looking out a couple of years.

Amit Kumar Singh executive
#41

Right now, oncology makes up nearly 10% of our total specialty mix. If you look back two to three years, that figure stood at under 4%. So we feel very confident that moving ahead — now that both of the new hospitals are fully operating as oncology service providers — oncology should reach roughly 15% in under two years. Perhaps in 1.5 years, we ought to get there.

Surya Narayan Nayak analyst
#42

Did we see any pickup in medical tourism during this quarter?

Amit Kumar Singh executive
#43

Yes, definitely. The figures have certainly gone up. In percentage terms, I'd still call it a single digit. But the initiatives the international team has undertaken are quite encouraging — the various OPD centers and the channel partners we brought on. So we believe that, in fact, Jewar Airport is likely to begin in about two months or so. That's a new deadline that has emerged. So we feel quite confident about these numbers. The absolute number has definitely risen. And beyond just the figures, you can see the geography — which we mentioned previously, I mean, over whatever eight, nine months, 10 months that we've been working on international — so we have reached various geographies. And it's quite encouraging that patients have come from all of those geographies. So at least a very solid base has been established. Now we simply need to capitalize on it.

Surya Narayan Nayak analyst
#44

On the mix of cases, aside from oncology, would it be fair to say things will stay roughly the same? Or do you expect any shift, say in neuroscience or elsewhere?

Amit Kumar Singh executive
#45

So overall, our emphasis is on growing the super specialty services rather than the specialties. That means in the case mix as well, you'll notice all the super specialties. So cardiology, neurosurgery, gastroenterology, and a few others taken together would be greater than, say, specialties such as gynecology, internal medicine, and basic orthopedic work. So that's the shift you'll observe in the years ahead, and we're already showing it quarter-on-quarter.

Surya Narayan Nayak analyst
#46

Do you have any guidance on ALOS as we move forward?

Amit Kumar Singh executive
#47

My view is that ALOS ought to follow the industry standard.

Surya Narayan Nayak analyst
#48

So moving forward, it should land at 3?

Amit Kumar Singh executive
#49

That figure should hold near that level, since a couple of new hospitals are in the pipeline. Some business is reaching out to me that I need to take on. So I'd say it will land somewhere close to 4 to 4.3. That's fairly acceptable. Anywhere within 4 to 4.5 strikes me as an acceptable number, and as you expand, likely two years down the line, if you ask me, it will definitely be lower.

Surya Narayan Nayak analyst
#50

Alright, thank you, sir. Appreciate it.

Operator operator
#51

Thanks. Ladies and gentlemen, so that management can get to questions from everyone on the call, we ask that each participant keep it to two questions. Up next we have Ishika calling from Perpetuity Ventures. Please go ahead.

Ishika Shah analyst
#52

Yeah. Hello. I hope you can hear me. Regarding the payer mix, your new hospitals appear to be powered mostly by cash and PPA insurance, with only a small contribution from government schemes. Is that mix structural and likely to persist, or do you expect a significant move toward government payers during the coming 12 to 24 months?

Amit Kumar Singh executive
#53

Look, this has been planned strategically and it's expected. As a group, we've always discussed lowering the government mix in the past, and that's exactly what we're doing now. I wouldn't claim it stays at zero a year from now. It will definitely go up. But in the new hospitals, I don't see the government mix exceeding somewhere around 15%-18%, or 20% at the absolute most. So in the end, that's what you'll see going forward. Ultimately, that's what will bring our debtor days and receivables down. So that's a strategic call we've made, and we're able to demonstrate it through a strong attraction of cash and private insurance patients.

Ishika Shah analyst
#54

Alright, got it. That was useful. Could you go over again, for each of your operating units, the occupancy by hospital and the RPOF for Q3 of FY26?

Nitin Gupta executive
#55

Right. So on a blended basis, total occupancy stands at 67%. At Greater Noida Hospital, occupancy is 74%. For Noida, it's 91%. Noida Extension comes in at 61%. Jhansi Orchha sits at 72%. Greater Faridabad is at 60%. Model Town is at 38%. And the new Faridabad hospital is at 43%. Overall, our ARPOB is INR 33,744, of which Greater Noida accounts for roughly INR 39,000. Noida is nearly INR 32,000. Noida Extension is close to INR 44,000. Jhansi Orchha is around INR 14,000. Greater Faridabad is approximately INR 35,000. Model Town is roughly INR 40,000. And the new Faridabad facility is nearly INR 36,000.

Ishika Shah analyst
#56

All right, thanks. That was really useful. Mind if I fit in a final question? You mentioned brownfield beds that were coming in for Greater Noida and Noida Extension. Where does that stand right now?

Amit Kumar Singh executive
#57

In about 1.5 years, my expectation is that we'll be nearing the point of getting them commissioned.

Ishika Shah analyst
#58

Alright. Thanks a lot — I really appreciate it.

Operator operator
#59

Thanks. Shreya Chatterjee from Ageless Capital is on the line with our next question. Go ahead, please.

Shreya Chatterjee analyst
#60

Hi, sir. Thanks for taking my question. What I was really asking is whether you could provide an EBITDA breakdown by hospital, and where you expect your EBITDA to ramp up over the next two to three years. Would it be around 29% or 30%, or would it stay in the 24%-25% range?

Amit Kumar Singh executive
#61

Look, on a unit-by-unit basis, EBITDA is something at this point — it wouldn't be the right way to estimate, because many new hospitals and older hospitals are in the process of starting up. So we always work it out at the consolidated level. And beyond that, we have certain subsidiaries, and certain hospitals sit inside the parent company. So taken altogether, two to three hospitals fall under the Yatharth Holding Company, and then there are two to three subsidiaries that make them up. So what I can speak to is the group-level EBITDA. So even when you look at it with the two new hospitals having started, even in that case, we are almost slightly — in fact, above the prior quarter when it comes to EBITDA margins. And absent those two new hospitals, we would have landed somewhere near 28%-29% EBITDA. So I think the company is very much on track toward the EBITDA we are targeting. We believe that over the coming quarters, EBITDA margins at the consolidated level will certainly rise, and the main reason is that in the first two quarters after a hospital opens — like New Delhi Hospital and Faridabad 20 — an EBITDA drag is to be expected. But come the third or the fourth quarter of their operations, that drag gets smaller. Also, on a very positive note, the Agra Hospital we have opened creates no EBITDA drag whatsoever.

Amit Kumar Singh executive
#62

That's another factor too — whatever it contributes is going to boost EBITDA. So we're pretty confident that over the coming quarters, EBITDA margins are going to rise. And no, we aren't aiming for 28%-29% EBITDA even, say, two to three years out, because new additions and new hospitals will keep coming. As we said before, we're looking to reach roughly 5,000-bed capacity over the next 3, 3.5 years. So that's going to mean plenty of EBITDA drags from the hospitals coming up. But on a consolidated basis, we think a 24%-25% EBITDA margin is about the right estimate. Yes, if you take out all the new hospitals we'll be starting, EBITDA margins would come in roughly 3%-3.5% above the consolidated average.

Shreya Chatterjee analyst
#63

Understood, sir. And given the payer mix you have at present, what would receivable days be at Q326? And where would you expect that figure to land, perhaps in FY27 to 28? Then on ARPOB — you've scaled it up quite impressively as of now. But maybe two years out, at the console level, where do you see ARPOB rising as oncology gains traction and the rest follows?

Amit Kumar Singh executive
#64

When we reported in September 2025, receivable days stood at roughly 116. By December, those days were also very, very near that same figure. We hold strong hope that we will end March 2027 with receivable days under 110.

Shreya Chatterjee analyst
#65

And looking ahead—say over the coming 2 years, when the government share, meaning CGHS's share, drops to roughly 25%-28%—what receivable days should we expect to see during that period?

Amit Kumar Singh executive
#66

Looking ahead two years, as we already said, our government mix is going to come down. We'll grow the cash and PPA side of the business. As we mentioned earlier, both hospitals we've launched operate solely on cash and PPA. Two or three years out, we'll be very close to 80 or 82 days.

Shreya Chatterjee analyst
#67

Understood, sir. And on the ARPOB guidance? That was simply a follow-on — the question just carried over. What would the ARPOB guidance look like, say, in FY 2027 to 2028?

Amit Kumar Singh executive
#68

Look, even with the latest figures, you can see we're posting more than 10% growth in ARPOB year-on-year. So I think that's pretty easy to work out from there. And with the current numbers you're seeing, the growth at Noida Extension, Greater Noida, and the other hospitals — so 10% ARPOB year-on-year, I think that's quite easily achievable for us. That's what our guidance is.

Shreya Chatterjee analyst
#69

All right, sir, thank you. I appreciate you taking the time to answer each of my questions.

Operator operator
#70

Thanks. We’ll take our next question from Nirali Shah at Ashika Stock Broking, who is on the line. Please go ahead.

Nirali Shah analyst
#71

Hi there. Congrats on the impressive results. I had a couple of things I wanted to ask. We had anticipated a bit of margin pressure because of the contribution from hospitals that recently opened. But as you mentioned, EBITDA margins have largely held steady QOQ as well. So my question is, what was it that helped offset that drag during this particular quarter? Were there any particular factors that we shouldn't assume will carry into Q4?

Amit Kumar Singh executive
#72

Okay, apologies — there's quite a bit of background noise on your line. So, we got a lot of good EBITDA traction from the hospitals we already have. Beyond the new hospitals, our existing ones are building up solid oncology business. They're also building up good ARPOB, right? So if you look at ARPOB, Noida Extension is up more than 15% year-on-year. Same with Greater Noida. So even our existing hospitals, the older ones, are growing at a solid rate. That's what has made this margin sustainable. And beyond that, if you look at our Model Town Hospital as well, we started it in Q2, and the losses have come down from Q2 to Q3. So in Q3, there's a 50% reduction in losses at Model Town Hospital itself. Yes. Also, looking ahead, with the new CGHS rate revision, which we saw in December, and which we'll now see from 1st January across the whole of quarter four, that will also help going forward and contribute significantly to our EBITDA margins.

Nirali Shah analyst
#73

Would it be reasonable to think that the margins at the older hospitals were considerably higher than any drag that newly opened hospitals might have created?

Amit Kumar Singh executive
#74

Yeah, you're right about that. That's correct. And like we said, in Q2 and Q3, the drag from the new hospitals was smaller too, thanks to the growth in the business.

Nirali Shah analyst
#75

But should we be expecting that in Q4 or perhaps Q1?

Amit Kumar Singh executive
#76

Right, absolutely, absolutely. Like I said, EBITDA margins ought to improve going forward over the quarters ahead, no question about it.

Nirali Shah analyst
#77

Got it. Could you also walk us through how much of that rise in employee expenses comes from the labor code change, and how much is down to ordinary hiring and the ramp-up at the newer hospitals?

Nitin Gupta executive
#78

Look, given the recent changes that have been brought about by the labor code, there isn’t any significant impact on us. As per the proposed codes, we are largely in line with our current stature. A minor impact, though, could come in the form of a change to the basic pay, which has been packaged into the gratuity. On other fronts, such as the bonus act or leave encashment, we don’t have any major impact. Overall, we believe a complete assessment is in place, and because of this new labor code, we don’t expect any major impact in this financial year.

Nirali Shah analyst
#79

Right. So if that doesn't land in this financial year, then it won't land in the next financial year either?

Nitin Gupta executive
#80

No, no. We're already matched to the proposed stature you're describing. Our stature is already in line. So there aren't any gaps that would create a major financial impact in this financial year. Obviously, by the next financial year, it will already be aligned. So no financial impact is going to come into play in the financials.

Nirali Shah analyst
#81

Great, great. And one final question — I'd like to ask about the MVT business, since there was some mention of the benefits, and the Union Budget did talk about encouraging medical tourism. So do you see any additional benefit coming our way?

Amit Kumar Singh executive
#82

Yeah. On that particular business, our estimate is that we'd see roughly a 5%-6% rise in cost, and that's the benefit we'd be getting from it.

Nirali Shah analyst
#83

Understood, thank you. There are additional questions I still have. I'll reconnect with you later.

Operator operator
#84

Thanks. We now have a question from Abhijit at PI Asset on the line. Go ahead, please.

Analyst analyst
#85

Appreciate the chance to speak. I hope you can hear me clearly. Sir, we're seeing a notable jump in other expenses. Did that stem from one-time marketing spend or from empowering star doctors? Should we expect those costs to come down in FY27, or ought we to model the same run rate?

Amit Kumar Singh executive
#86

So on a consolidated basis, you're seeing growth from one quarter to the next, and that's mainly driven by the hospitals we've newly added. At both of those new facilities, we've brought on the full doctor cost. That alone explains it. The shift is essentially all down to physician cost. Looking at our existing hospitals, nothing significant has changed. Yeah.

Analyst analyst
#87

So, should we be ramping that up at the new-normal rate for the year?

Amit Kumar Singh executive
#88

Right, so this is normal at this point, and we won't see any significant increase from here.

Analyst analyst
#89

Got it. And sir, regarding FY27, what does CapEx come to? I didn’t catch that from you.

Amit Kumar Singh executive
#90

Would you mind repeating that?

Analyst analyst
#91

What's the capex number for FY27?

Amit Kumar Singh executive
#92

We've set out a total Capex plan covering the coming five years. The deals themselves will be announced inside roughly 3 to 3.5 years. However, the full deployment of that Capex will stretch across five years, and it comes to about INR 1,500 crore, which gets us to a bed capacity of nearly 5,000 beds.

Analyst analyst
#93

Got it. All right. Thanks.

Operator operator
#94

Thanks. We’ll take our next question from Akshat Mehta at Seven Rivers Holdings. Please go ahead.

Akshat Mehta analyst
#95

Hello there. Can you hear me okay, sir?

Amit Kumar Singh executive
#96

Yeah, yeah, yeah, yeah, yeah.

Akshat Mehta analyst
#97

Yeah. So the first thing I'd like to ask Yatharth himself is this: if you take the overall trade receivable days in the business as 110, and assume that 35% of the business comes from your government and 65% is split evenly between cash and PPA, that would suggest your government business receivable days are north of 245, 250 days. Is that the right way to look at it?

Amit Kumar Singh executive
#98

I mean, some payers—within TPS as well, let's say—do cause a drag, since most of the PPA business gets paid on schedule. That said, there are exceptions in certain cases. So that plays a part too. Still, yes, I'd say what you described is close, though not exactly to that amount.

Akshat Mehta analyst
#99

It differs from case to case, and even within government. Yet some other listed payers have said their receivable days on government business come in under 150 — 140 days. So how come ours sit nearer 250, and what exactly are we doing to get that figure lower?

Amit Kumar Singh executive
#100

Well, I don't believe it's nearer to 250 — I'd say it's nearer to 200, first of all. And secondly, as we've said before, there was a specific reason this happened, particularly if you go back a year, when we scaled up with the infrastructure — we took on a lot of government business, correct? So our systems and processes needed time for us to upgrade them, right? It isn't that the government is 100% responsible — only the receivables. There are certain frameworks and systems inside the hospital that enable quicker recovery. So initially we didn't have those in place. If I speak about the past 12 months, the reason we've produced roughly 60%-70% OCF to EBITDA is the way we've streamlined the process. In fact, lately, certain teams have been outsourced for collections to secure faster recovery, and those teams already work for some other hospitals that you've named. So we've taken a lesson from their example and rolled out that same network of facilities within our hospital. So that too has contributed to this reduction. Beyond simply the decline in the government share, which will in the end bring this down, improved recovery and better follow-ups on our side are also helping us get there.

Akshat Mehta analyst
#101

Understood. My follow-up question concerns trade receivables.

Amit Kumar Singh executive
#102

Also, sorry — just one final item I’d like to ask about. You brought up other hospital chains, and a number of those don’t have the same payer/government mix as ours, correct? There’s a government payer known as ESI that many other hospital chains simply don’t deal with. Historically, ESI has typically been shown to have a slow payment cycle. And I’d say roughly 30%-35% of what we have outstanding with the government comes specifically from ESI channels. So that has contributed to an increase as well, and it isn’t standard across other hospital chains.

Akshat Mehta analyst
#103

All right, that makes it clear. Thanks. My follow-up is about trade receivables once more. Your annual report showed a decrease in total trade receivables of INR 20 crore. For FY 2024, the figure stood at roughly INR 35 crore. That implies a drop of nearly 6% and 11%, respectively. What drove that decrease, and how should we view it going forward?

Amit Kumar Singh executive
#104

This is based on the collections side, as we mentioned earlier, correct? So for the past 1 or more than 1 year, we've been focusing on rigorous collections. We've put all the protocols in place to achieve better billing processes, better dispatch processes, and all the recovery processes.

Akshat Mehta analyst
#105

Actually, what I'm referring to is a write-off related to trade receivables.

Amit Kumar Singh executive
#106

On write-offs — as a matter of prudence, we typically carry a provision for doubtful debts. That said, the bad debts we see are very minuscule, and as of now we have none at all. The provision is made on prudence grounds, following accounting principles. Looking at trends, though, our deductions are declining, and generally our provision has been reversing over the period. So. Yeah. Essentially, what you're referring to as well — a deduction isn't a write-off of any debt; it's certain bills that the payer mix contests, and that's what the deduction amounts to. For instance, with any private insurance company, certain deductions occur on a bill basis. So that was the situation.

Akshat Mehta analyst
#107

What's the right way for us to think about this going forward? Should we expect a comparable percentage in future years and quarters too?

Amit Kumar Singh executive
#108

At the group level, our overall deduction has been coming down over the last two years. You can see that in the results we reported as well. We'll stick with that same trend, though it isn't 1% or 2%. Yes, it will go lower. At the same time, we're also setting aside a provision for the amount we haven't collected.

Akshat Mehta analyst
#109

Understood. That's clear now. Thanks. And well done on a solid set of results. Thanks.

Operator operator
#110

Thanks. We now have a question from Shubham Harne with Purnartha Investment Advisors, who is on the line. Go right ahead.

Shubham Harne analyst
#111

Thank you for the chance to address that, sir. What dangers do you anticipate stemming from new chain hospitals moving into the Noida area?

Amit Kumar Singh executive
#112

Look, I think instead of viewing it as a risk, we actually see it as beneficial for our business, because whenever more and more hospitals arrive in any territory, that territory gets developed. As a result, your catchment rates go up. People come. So I think everybody will have a — let me give you an example. In our own territory, two or three new hospitals have opened with new brands and new entrants. Yet despite that, I think we've grown by more than 30%. And at an existing hospital, I see growth of more than 25%. So it really all depends on how you look at it, right? We personally believe that yes, you need to be aware of what your competitor is doing. But if you're working from your core strength and more and more players keep coming in, then stay focused. Stay in the limelight. People will always come to you. That's fine. To be very honest, we don't see any reduction in the pie.

Shubham Harne analyst
#113

Do you think there's any chance doctors could get pushed from your institute over to another one?

Amit Kumar Singh executive
#114

Sure, that's just how it works. Trust me, whenever any hospital moves into a new area, they check who's performing well and which physicians are strong. We do the same thing, correct? When we went into Delhi, we followed that same approach. When we went into Faridabad, we followed that same approach. So that's just how it works. And as a hospital, we're ready for it, right? So it's one go, and others can come along too. That's just the way it is.

Shubham Harne analyst
#115

Understood. Thanks, sir.

Operator operator
#116

Thanks. The next question comes from Akhilesh Rawat with Ridhanta Vision Private Limited. Go ahead, please. Mr. Rawat, we've unmuted your line. Yes, please proceed.

Akhilesh Rawat analyst
#117

Hello there. Hello. To begin with, I want to say congratulations to the management team on a solid set of results. I have just one brief question, and that will cover everything I wanted to ask. I'd simply like to get a sense of where our receivable days stand right now. For the group, meaning all group hospitals.

Amit Kumar Singh executive
#118

At the consolidated group level, receivable days right now sit at roughly 115 days. As I said in response to the earlier question, that figure is going to come down, landing somewhere between 105 and 110 by March 2027.

Akhilesh Rawat analyst
#119

Yeah. Thanks. That’s all I had to say. Thanks.

Operator operator
#120

Thanks. We now have a question from Anand B at KSEMA Wealth Management on the line. Go right ahead.

Anand Bhaskaran analyst
#121

Hey, congrats on a solid set of numbers. I’ve just got two questions. First, is that IT issue fully fixed at this point?

Amit Kumar Singh executive
#122

Right. So every attachment has been lifted, along with the freeze on any asset or anything of that kind. We're now in the final stages, and we expect this matter to be resolved very soon. So yes, things are proceeding according to plan.

Anand Bhaskaran analyst
#123

What's your sense of when this matter will be fully wrapped up? You provided us with some kind of timeline, quarterly or thereabouts.

Amit Kumar Singh executive
#124

These are industry standard, you know. And at some point over the next few quarters, it definitely will. Even though the issue that was being focused on has already been settled in the previous quarter. So for us, what's left is really just a formality at this point.

Anand Bhaskaran analyst
#125

All right, all right. For my last question, could you go over the ARPOB figures for every one of the hospitals once more? And what do you expect ARPOB to be, say, in FY27 and FY28, for each hospital individually?

Amit Kumar Singh executive
#126

Right, so on a blended basis, our RPOB comes to INR 33,744, and within that we can say Greater Noida has an RPOB of nearly about INR 39,000. At Noida Hospital, our RPOB is nearly INR 32,000. For Noida Extension, our RPOB stands at nearly around INR 44,000. Jhansi Orchha, our RPOB is INR 14,000. Greater Faridabad, that hospital has an RPOB of nearly INR 34,000. Model Town, we have an RPOB of INR 40,000. And the new Faridabad one, our RPOB is INR 36,000.

Anand Bhaskaran analyst
#127

All right. So where exactly are you seeing that RPOB?

Amit Kumar Singh executive
#128

As you can observe, the pattern we're tracking shows roughly a 10% increase annually on a year-over-year basis. In the same manner, we anticipate seeing approximately another 10% of growth during the upcoming period.

Anand Bhaskaran analyst
#129

Understood. You said Agra's RPOB expectation sits at roughly INR 30,000 to 32,000. For the newer hospitals, though — Delhi and Faridabad — are you expecting something comparable in FY 2027 and FY 2028 as well?

Amit Kumar Singh executive
#130

Right, right. The territory we're covering in Delhi and Faridabad differs from Agra. For Agra, we expect the ARPOB to come in around 30,000 as well. And for a Tier 2 city territory, that's a solid ARPOB.

Anand Bhaskaran analyst
#131

Alright, the ARPOB for a Tier 2 city. Alright, thanks.

Operator operator
#132

Thanks. We’ll take the next question from Umakant at Viansh Ventures Private Limited. Your line is open — please go ahead.

Umakant Sharma analyst
#133

Yeah. Hi, Chief. Congrats on a solid set of numbers. Most of my questions have been answered. I've just got one quick question. Could you just touch a little bit on the margin profile — where do we stand currently at your Greater Faridabad Hospital as well as the Model Town? The reason I'm asking is because I just want clarity in terms of how much more use do we further have to scale up the mature hospital margin profile from 29%? Can it go to, let's say, a further X percentage? So, if you could just throw some color around that. And even on the Jhansi, what's the margin profile currently?

Amit Kumar Singh executive
#134

As we said, if you take out the newer hospitals at Model Town and Sector 20 — right, Sector 20 and Greater Faridabad are two separate hospitals — so excluding Sector 20 and Model Town, group margins come to 29%. The biggest contributors within that, though, are Greater Noida, Sector 100 and Noida, and Noida Extension, since those were started earlier. Take hospitals such as Jhansi, or even Greater Faridabad, which began about 2 years and 1.5 years ago — there the margin would still be approaching 20% or above. But the 29% figure you're seeing on a consolidated basis without the new hospital is mainly driven by the Noida hospitals. Looking ahead, though, even excluding the newer hospitals, we don't expect margins to climb sharply beyond these levels, because although occupancy ramp-up will occur, there is high-quality growth taking place, right? We're growing ARPOB-wise as well. We're also shifting our payer mix. We're cutting government pay, not only at the new hospitals but at our earlier ones too. So there are certain cost expenditures we have to incur for that.

Amit Kumar Singh executive
#135

As for the other new hospitals, margins would stay roughly along the same lines and won't rise meaningfully.

Umakant Sharma analyst
#136

All right, understood. To build on that point, regarding the first question: when we mention that we've taken a loss of roughly INR 10 crore at our newer hospital — that's Sector 20 and Model Town — we've actually run losses of around INR 20 crore at our operational level. Now, once we reach a certain point, we'll be ramping it up. So, do we anticipate these losses growing larger before margins begin to expand and this turns positive? And second, what occupancy do we — let's say, when do we expect to see a healthy occupancy level at these two hospitals?

Amit Kumar Singh executive
#137

No, sir, the biggest one, as we said before — so every cost center you're seeing, all those expenditures, were mainly for the newer hospitals, and the doctor cost plus the employee cost are already in place. Now, the cost tied to your business. So in the coming quarters, those losses should show up. And what I can tell you is, I think with Faridabad, we'll probably reach break-even much sooner. In fact, likely well inside the 12 months, which would be a really strong set of — I mean, that's what the expectation is, and given the kind of business trend we've seen over the last three months. Likewise, Model Town, which we're looking at, I think within the 15 months, we should have an operational break-even there. So we don't see any losses arising. Whatever losses there would be, they're directly proportional to whatever business we acquire. What was your second question? I missed it.

Umakant Sharma analyst
#138

On occupancy for these two, at what point do we get to a healthy occupancy level?

Amit Kumar Singh executive
#139

Right now, if we look at full-fledged operations, Faridabad is running roughly 125 operational beds, and Model Town has about 120 beds. But once Model Town is fully up as a 300-bed facility and Faridabad as a 400-bed one, I think break-even will come at somewhere between 30% and 35% of fully operational beds. And then, as I mentioned earlier, probably within 12 months or 15 months, I think we would very much hit those targets.

Umakant Sharma analyst
#140

Understood. All right. For my second question, I wanted to see if you could share any additional details about your plans for expansion going forward — would that growth come mainly through greenfield or brownfield projects? And in the case of brownfield, in the case of brownfield, what sort of size are we talking about? Also, what would the capex be, say, per bed that you're comfortable with? And a bit of color on geography as well.

Amit Kumar Singh executive
#141

As we said earlier, our goal is to get to nearly 5,000 beds over the coming three years when it comes to deals we've announced. Deployment, naturally, may stretch across the next four to five years, since the expansion will combine greenfield, brownfield, and asset-light formats. For this, the total Capex we're planning comes to roughly INR 1,500 crore. That works out to about INR 60 lakh per bed, given the blend of greenfield and asset-light. Geographically, this will sit in our first-priority region, NCR, and also in the second priority, namely major cities across North India.

Umakant Sharma analyst
#142

Just to clarify one thing. When you mention that we're aiming for INR 1,500 crore of Capex, my assumption is that this refers only to the INR 2,000 of the incremental piece, since we've already made plans for INR 6,500 brownfield, correct? In Noida and Noida Extension, we've already planned that. So, INR 2,000 for INR 1,500. That's what we're saying.

Amit Kumar Singh executive
#143

Yeah.

Umakant Sharma analyst
#144

Right, right, exactly — Ajay. So what we're saying is we'll land right at INR 60 lakhs. That's a pretty small figure, isn't it? I mean, if we pull it off, that's great.

Amit Kumar Singh executive
#145

Right, and asset-light models exist as well. So there are asset-light approaches in which we don't put money into land and buildings. We'd only be supplying the equipment. Those kinds of models are also something we're looking into.

Umakant Sharma analyst
#146

Oh, wow. All right. Wonderful, wonderful. I’ve got nothing further to add. Thanks very much.

Operator operator
#147

Thanks. We'll take the next question from Shubhanu Bangal at 3Head Capital. Your line is open.

Shubhanu Bangal analyst
#148

Yes, I hope you can hear me. Good afternoon. Sir, as you said, Q4 is going to be stronger than Q3, and the EBITDA margin is set to improve as we move ahead. What level of EBITDA margin are we aiming for in FY27? That is my first question.

Amit Kumar Singh executive
#149

Like we've said, we're in a phase of growth. We'll continue bringing on additional hospitals, and we'll ramp up the most recent hospital additions. For the blended EBITDA margin, our guidance is a range of 24%-25% at the consolidated level. Does that make sense to you?

Operator operator
#150

Hold on one moment, sir — I believe the connection dropped. Since no more questions remain, I’d like to turn the conference back to management for closing remarks.

Amit Kumar Singh executive
#151

Thank you, everyone. Thanks for joining the earnings conference call of Yatharth Hospital & Trauma Care Services Limited for the quarter that ended on December 31, 2025. We hope all of your questions have been answered. And thank you for asking them.

Operator operator
#152

Thanks. That brings this conference to a close on behalf of Nuvama Wealth Management Limited. We appreciate your participation, and you're welcome to continue the discussion now. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Yatharth Hospital & Trauma Care Services Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Yatharth Hospital & Trauma Care Services Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.